Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter Study
In this real-world cohort of European patients with unresectable HCC, the outcome of sorafenib treatment in the 2L setting was comparable to that of the other established 2L treatment options in patients with preserved liver function and good performance status. This study contributes to the understanding of the role of sorafenib in the 2L setting and underscores the need for further research to identify predictive factors for response and survival in order to optimize treatment algorithms for advanced HCC.
Authors
- Tom Luedde (ORCID: https://orcid.org/0000-0002-6288-8821)
- Angelo Pirozzi (ORCID: https://orcid.org/0000-0001-8603-0312)
- Arndt Weinmann (ORCID: https://orcid.org/0000-0003-1198-1716)
- Peter L. Schrammen
- Ursula Ehmer (ORCID: https://orcid.org/0000-0002-0441-1953)
- Najib Ben Khaled (ORCID: https://orcid.org/0000-0002-9681-2542)
- Anna Lena Saborowski (ORCID: https://orcid.org/0000-0003-4857-4276)
- Christian Möhring (ORCID: https://orcid.org/0000-0001-7651-4401)
- Maria Angeles Gonzalez-Carmona (ORCID: https://orcid.org/0000-0003-3956-1457)
- Ulrike Bauer (ORCID: https://orcid.org/0000-0003-2838-2840)
- Sabrina Welland (ORCID: https://orcid.org/0000-0003-1777-1322)
- Christoph Roderburg (ORCID: https://orcid.org/0000-0002-1409-7697)
- Malte B. Monin (ORCID: https://orcid.org/0000-0002-8794-3612)
- Enrico Narciso De Toni (ORCID: https://orcid.org/0000-0002-8101-8207)
- Matthias Pinter (ORCID: https://orcid.org/0000-0002-7260-532X)
- Birgit Schwacha-Eipper
- Marino Venerito (ORCID: https://orcid.org/0000-0001-8581-0974)
- Lorenza Rimassa (ORCID: https://orcid.org/0000-0001-9957-3615)
- Friedrich Sinner (ORCID: https://orcid.org/0000-0003-0524-8833)
- Thomas J. Ettrich (ORCID: https://orcid.org/0000-0002-7654-2442)
- Marie‐Luise Berres (ORCID: https://orcid.org/0000-0002-8009-948X)
- Arndt Vogel (ORCID: https://orcid.org/0000-0003-0560-5538)
- Moritz Berger (ORCID: https://orcid.org/0000-0002-0656-5286)
- Kateryna Shmanko (ORCID: https://orcid.org/0009-0001-0025-7100)
- Farsaneh Sadeghlar
- Lorenz Balcar (ORCID: https://orcid.org/0000-0002-6708-3061)
- Taotao Zhou (ORCID: https://orcid.org/0000-0002-8043-5818)
- Matthias Schmid
- Xin Zhou (ORCID: https://orcid.org/0000-0002-1854-1337)
- Ingo G.H. Schmidt‐Wolf
- C.P. Strassburg
- Iuliana‐Pompilia Radu
- Jörg C. Kalff (ORCID: https://orcid.org/0000-0001-5160-8671)
Institutions
- University of Bern (CH)
- Humanitas University (IT)
- University of Bonn (DE)
- Johannes Gutenberg University Mainz (DE)
- Heidelberg University (DE)
- University Hospital Bonn (DE)
- University Hospital of Bern (CH)
- Toronto General Hospital (CA)
- University Hospital Heidelberg (DE)
- LMU Klinikum (DE)
- Medizinische Hochschule Hannover (DE)
- Düsseldorf University Hospital (DE)
- Institut für Medizinische Biometrie, Informatik und Epidemiologie (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Central Institute of Mental Health (DE)
- Infektionsmedizinisches Centrum Hamburg (DE)
- Universitätsklinikum Aachen (DE)
- University Hospital Ulm (DE)
- Bundeswehrzentralkrankenhaus Koblenz (DE)
- IRCCS Humanitas Research Hospital (IT)
- Bundeswehr
- Heinrich Heine University Düsseldorf (DE)
- Technical University of Munich (DE)
- Medical University of Vienna (AT)
- Ludwig-Maximilians-Universität München (DE)
- Otto-von-Guericke-Universität Magdeburg (DE)
Publication Details
- Journal
- Cancers
- Published
- 2025-03-13
- DOI
- https://doi.org/10.3390/cancers17060972
- Citations
- 3
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 3.97